{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:14:31Z","timestamp":1792134871802,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00259-022-06044-9","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T08:48:03Z","timestamp":1669884483000},"page":"1195-1204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-0163","authenticated-orcid":false,"given":"No\u00e9mie S.","family":"Minczeles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eelke M.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinoud C.","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan M.","family":"Kros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Konijnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacoline E. C.","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens M. F.","family":"Dirven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Brabander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"6044_CR1","doi-asserted-by":"publisher","unstructured":"Ogasawara C, Philbrick BD, Adamson DC. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines. 2021:9. https:\/\/doi.org\/10.3390\/biomedicines9030319.","DOI":"10.3390\/biomedicines9030319"},{"key":"6044_CR2","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-Oncology. 2019;21:v1\u2013v100. https:\/\/doi.org\/10.1093\/neuonc\/noz150.","journal-title":"Neuro-Oncology"},{"key":"6044_CR3","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncology. 2021;23:1821\u201334. https:\/\/doi.org\/10.1093\/neuonc\/noab150.","journal-title":"Neuro-Oncology"},{"key":"6044_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3171\/2015.9.JNS15754","volume":"125","author":"K Gousias","year":"2016","unstructured":"Gousias K, Schramm J, Simon M. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. J Neurosurg. 2016;125:551\u201360. https:\/\/doi.org\/10.3171\/2015.9.JNS15754.","journal-title":"J Neurosurg"},{"key":"6044_CR5","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3171\/2009.9.JNS09617","volume":"112","author":"SL McGovern","year":"2010","unstructured":"McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg. 2010;112:925\u201333. https:\/\/doi.org\/10.3171\/2009.9.JNS09617.","journal-title":"J Neurosurg"},{"key":"6044_CR6","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/j.wneu.2017.10.028","volume":"109","author":"JS Ehresman","year":"2018","unstructured":"Ehresman JS, Garzon-Muvdi T, Rogers D, Lim M, Gallia GL, Weingart J, et al. The relevance of Simpson grade resections in modern neurosurgical treatment of World Health Organization grade I, II, and III meningiomas. World Neurosurg. 2018;109:e588\u2013e93. https:\/\/doi.org\/10.1016\/j.wneu.2017.10.028.","journal-title":"World Neurosurg"},{"key":"6044_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3171\/2014.7.JNS131644","volume":"122","author":"L Rogers","year":"2015","unstructured":"Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review J Neurosurg. 2015;122:4\u201323. https:\/\/doi.org\/10.3171\/2014.7.JNS131644.","journal-title":"A RANO review J Neurosurg"},{"key":"6044_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/neuonc\/not330","volume":"16","author":"T Kaley","year":"2014","unstructured":"Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncology. 2014;16:829\u201340. https:\/\/doi.org\/10.1093\/neuonc\/not330.","journal-title":"Neuro-Oncology"},{"key":"6044_CR9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304.","journal-title":"Ann Oncol"},{"key":"6044_CR10","first-page":"13185","volume":"8","author":"CB Silva","year":"2015","unstructured":"Silva CB, Ongaratti BR, Trott G, Haag T, Ferreira NP, Leaes CG, et al. Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. Int J Clin Exp Pathol. 2015;8:13185\u201392.","journal-title":"Int J Clin Exp Pathol"},{"key":"6044_CR11","first-page":"485","volume":"20","author":"V Barresi","year":"2008","unstructured":"Barresi V, Alafaci C, Salpietro F, Tuccari G. Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep. 2008;20:485\u201392.","journal-title":"Oncol Rep"},{"key":"6044_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/b:neon.0000013498.19981.55","volume":"66","author":"S Arena","year":"2004","unstructured":"Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neuro-Oncol. 2004;66:155\u201366. https:\/\/doi.org\/10.1023\/b:neon.0000013498.19981.55.","journal-title":"J Neuro-Oncol"},{"key":"6044_CR13","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00259-012-2155-3","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of (6)(8)Ga-DOTATOC PET\/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39:1409\u201315. https:\/\/doi.org\/10.1007\/s00259-012-2155-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6044_CR14","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s00259-020-04759-1","volume":"47","author":"A Bashir","year":"2020","unstructured":"Bashir A, Vestergaard MB, Binderup T, Broholm H, Marner L, Ziebell M, et al. Pharmacokinetic analysis of [(68)Ga]Ga-DOTA-TOC PET in meningiomas for assessment of in vivo somatostatin receptor subtype 2. Eur J Nucl Med Mol Imaging. 2020;47:2577\u201388. https:\/\/doi.org\/10.1007\/s00259-020-04759-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6044_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2967\/jnumed.114.149120","volume":"56","author":"W Rachinger","year":"2015","unstructured":"Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Poschl J, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56:347\u201353. https:\/\/doi.org\/10.2967\/jnumed.114.149120.","journal-title":"J Nucl Med"},{"key":"6044_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2967\/jnumed.120.249607","volume":"62","author":"C Mirian","year":"2021","unstructured":"Mirian C, Duun-Henriksen AK, Maier A, Pedersen MM, Jensen LR, Bashir A, et al. Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: individual patient data meta-analysis. J Nucl Med. 2021;62:507\u201313. https:\/\/doi.org\/10.2967\/jnumed.120.249607.","journal-title":"J Nucl Med"},{"key":"6044_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2967\/jnumed.114.147256","volume":"56","author":"N Marincek","year":"2015","unstructured":"Marincek N, Radojewski P, Dumont RA, Brunner P, Muller-Brand J, Maecke HR, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015;56:171\u20136. https:\/\/doi.org\/10.2967\/jnumed.114.147256.","journal-title":"J Nucl Med"},{"key":"6044_CR18","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","volume":"36","author":"M Bartolomei","year":"2009","unstructured":"Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009;36:1407\u201316. https:\/\/doi.org\/10.1007\/s00259-009-1115-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6044_CR19","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/neuonc\/now060","volume":"18","author":"K Seystahl","year":"2016","unstructured":"Seystahl K, Stoecklein V, Schuller U, Rushing E, Nicolas G, Schafer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake. Neuro-Oncology. 2016;18:1538\u201347. https:\/\/doi.org\/10.1093\/neuonc\/now060.","journal-title":"Neuro-Oncology"},{"key":"6044_CR20","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","volume":"56","author":"K Gerster-Gillieron","year":"2015","unstructured":"Gerster-Gillieron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med. 2015;56:1748\u201351. https:\/\/doi.org\/10.2967\/jnumed.115.155853.","journal-title":"J Nucl Med"},{"key":"6044_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/cbr.2013.1599","volume":"29","author":"F Minutoli","year":"2014","unstructured":"Minutoli F, Amato E, Sindoni A, Cardile D, Conti A, Herberg A, et al. Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature. Cancer Biother Radiopharm. 2014;29:193\u20139. https:\/\/doi.org\/10.1089\/cbr.2013.1599.","journal-title":"Cancer Biother Radiopharm"},{"key":"6044_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ctro.2020.03.002","volume":"22","author":"PE Hartrampf","year":"2020","unstructured":"Hartrampf PE, Hanscheid H, Kertels O, Schirbel A, Kreissl MC, Flentje M, et al. Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol. 2020;22:29\u201332. https:\/\/doi.org\/10.1016\/j.ctro.2020.03.002.","journal-title":"Clin Transl Radiat Oncol"},{"key":"6044_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1748-717X-7-99","volume":"7","author":"MC Kreissl","year":"2012","unstructured":"Kreissl MC, Hanscheid H, Lohr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012;7:99. https:\/\/doi.org\/10.1186\/1748-717X-7-99.","journal-title":"Radiat Oncol"},{"key":"6044_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/a-1200-0989","volume":"59","author":"M Muther","year":"2020","unstructured":"Muther M, Roll W, Brokinkel B, Zinnhardt B, Sporns PB, Seifert R, et al. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma. Nuklearmedizin. 2020;59:348\u201355. https:\/\/doi.org\/10.1055\/a-1200-0989.","journal-title":"Nuklearmedizin"},{"key":"6044_CR25","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743.","journal-title":"Clin Cancer Res"},{"key":"6044_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/neuonc\/noy137","volume":"21","author":"RY Huang","year":"2019","unstructured":"Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, et al. Proposed response assessment and endpoints for meningioma clinical trials: report from the response assessment in neuro-oncology working group. Neuro-Oncology. 2019;21:26\u201336. https:\/\/doi.org\/10.1093\/neuonc\/noy137.","journal-title":"Neuro-Oncology"},{"key":"6044_CR27","unstructured":"US Department of Health and Human Services, National Institute of health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 4.03. 2010; Accessed September 2021. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"6044_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G. Thomas Sr. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med. 2009;50:477\u201384. https:\/\/doi.org\/10.2967\/jnumed.108.056036.","journal-title":"J Nucl Med"},{"key":"6044_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40658-020-0278-3","volume":"7","author":"SMB Peters","year":"2020","unstructured":"Peters SMB, Meyer Viol SL, van der Werf NR, de Jong N, van Velden FHP, Meeuwis A, et al. Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT\/CT systems. EJNMMI Phys. 2020;7:9. https:\/\/doi.org\/10.1186\/s40658-020-0278-3.","journal-title":"EJNMMI Phys"},{"key":"6044_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","volume":"7","author":"M Andersson","year":"2017","unstructured":"Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7:88. https:\/\/doi.org\/10.1186\/s13550-017-0339-3.","journal-title":"EJNMMI Res"},{"key":"6044_CR31","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803\u201320. https:\/\/doi.org\/10.1007\/s00401-016-1545-1.","journal-title":"Acta Neuropathol"},{"key":"6044_CR32","doi-asserted-by":"publisher","unstructured":"Preusser M, Silvani A, Le Rhun E, Soffietti R, Lombardi G, Sepulveda JM, et al. Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC brain tumor group (EORTC-1320-BTG). Neuro-Oncology. 2021. https:\/\/doi.org\/10.1093\/neuonc\/noab243.","DOI":"10.1093\/neuonc\/noab243"},{"key":"6044_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"6044_CR34","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1089\/cbr.2009.0641","volume":"24","author":"ML Sierra","year":"2009","unstructured":"Sierra ML, Agazzi A, Bodei L, Pacifici M, Arico D, De Cicco C, et al. Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC. Cancer Biother Radiopharm. 2009;24:659\u201365. https:\/\/doi.org\/10.1089\/cbr.2009.0641.","journal-title":"Cancer Biother Radiopharm"},{"key":"6044_CR35","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.2174\/1568026620666200226104652","volume":"20","author":"D Feijtel","year":"2020","unstructured":"Feijtel D, de Jong M, Nonnekens J. Peptide receptor radionuclide therapy: looking back, looking forward. Curr Top Med Chem. 2020;20:2959\u201369. https:\/\/doi.org\/10.2174\/1568026620666200226104652.","journal-title":"Curr Top Med Chem"},{"key":"6044_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.canlet.2011.08.022","volume":"313","author":"VR Gogineni","year":"2011","unstructured":"Gogineni VR, Nalla AK, Gupta R, Dinh DH, Klopfenstein JD, Rao JS. Chk2-mediated G2\/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett. 2011;313:64\u201375. https:\/\/doi.org\/10.1016\/j.canlet.2011.08.022.","journal-title":"Cancer Lett"},{"key":"6044_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neuchi.2014.10.112","volume":"64","author":"J Biau","year":"2018","unstructured":"Biau J, Khalil T, Verrelle P, Lemaire JJ. Fractionated radiotherapy and radiosurgery of intracranial meningiomas. Neurochirurgie. 2018;64:29\u201336. https:\/\/doi.org\/10.1016\/j.neuchi.2014.10.112.","journal-title":"Neurochirurgie"},{"key":"6044_CR38","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Central nervous system cancers. Version 2.2021. Accessed April 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf."},{"key":"6044_CR39","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/neuonc\/noab019","volume":"23","author":"T Graillon","year":"2021","unstructured":"Graillon T, Ferrer L, Siffre J, Sanson M, Peyre M, Peyriere H, et al. Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study. Neuro-Oncology. 2021;23:1139\u201347. https:\/\/doi.org\/10.1093\/neuonc\/noab019.","journal-title":"Neuro-Oncology"},{"key":"6044_CR40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/neuonc\/now001","volume":"18","author":"M Sommerauer","year":"2016","unstructured":"Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, et al. 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro-Oncology. 2016;18:1021\u20137. https:\/\/doi.org\/10.1093\/neuonc\/now001.","journal-title":"Neuro-Oncology"},{"key":"6044_CR41","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3171\/2008.8.JNS08481","volume":"110","author":"T Hashiba","year":"2009","unstructured":"Hashiba T, Hashimoto N, Izumoto S, Suzuki T, Kagawa N, Maruno M, et al. Serial volumetric assessment of the natural history and growth pattern of incidentally discovered meningiomas. J Neurosurg. 2009;110:675\u201384. https:\/\/doi.org\/10.3171\/2008.8.JNS08481.","journal-title":"J Neurosurg"},{"key":"6044_CR42","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3171\/2010.12.JNS101623","volume":"114","author":"S Oya","year":"2011","unstructured":"Oya S, Kim SH, Sade B, Lee JH. The natural history of intracranial meningiomas. J Neurosurg. 2011;114:1250\u20136. https:\/\/doi.org\/10.3171\/2010.12.JNS101623.","journal-title":"J Neurosurg"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06044-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-06044-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06044-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T22:09:42Z","timestamp":1676498982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-06044-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["6044"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-06044-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"27 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Erasmus Medical Centre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all subjects involved in the study, or the need for written informed consent was waived by the medical ethical committee of the Erasmus MC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all subjects involved in the study, or the need for written informed consent was waived by the medical ethical committee of the Erasmus MC.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E.M.B has received consultancy fees from BrainLab A.G. W.W.D.H has received speaker fees from AAA-Novartis and Ipsen, compensation from AAA-Novartis and Ipsen for service on advisory boards, and research support from AAA-Novartis. J.H. has received speaker fees from Ipsen and compensation from AAA-Novartis and Ipsen for service on advisory boards. T.B. has received speaker fees from AAA-Novartis and Ipsen, compensation from AAA-Novartis for service on advisory board, and research support from AAA-Novartis. The other authors have no disclosures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}